18F-FDG PET Imaging of Murine Atherosclerosis: Association with Gene Expression of Key Molecular Markers

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Hag, Anne Mette Fisker ^a   Pedersen, Sune Folke ^a   Christoffersen, Christina ^b   Binderup, Tina ^a   Jensen, Mette Munk ^a   Jørgensen, Jesper Tranekjær ^a   Skovgaard, Dorthe ^a   Ripa, Rasmus Sejersten ^a   Kjaer, Andreas ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; BIOLOGICAL MARKER; CXCL1 CHEMOKINE; FLUORODEOXYGLUCOSE F 18; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; MOLECULAR MARKER; MONOCYTE CHEMOTACTIC PROTEIN 1; OSTEOPONTIN; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR 1; PROTEIN CD68; RNA; THROMBOPLASTIN; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN A;

ANIMAL EUTHANASIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; CORRELATION ANALYSIS; EX VIVO STUDY; GENE EXPRESSION; GENETIC ASSOCIATION; LIPID DIET; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; POSITRON EMISSION TOMOGRAPHY; RNA EXTRACTION;

ANIMALS; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; FLUORODEOXYGLUCOSE F18; GENE EXPRESSION REGULATION; LINEAR MODELS; MICE; MULTIVARIATE ANALYSIS; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, X-RAY COMPUTED;

ANIMALIA; MURINAE; MUS;

EID: 84870622989     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0050908     Document Type: Article

References (46)

1. Rudd JHF, Warburton EA, Fryer TD, Jones HA, Clark JC, et al. (2002) Imaging atherosclerotic plaque inflammation with [18F]-fluorodeoxyglucose positron emission tomography. Circulation 105: 2708-2711.
2. Tawakol A, Migrino RQ, Hoffmann U, Abbara S, Houser S, et al. (2005) Noninvasive in vivo measurement of vascular inflammation with F-18 fluorodeoxyglucose positron emission tomography. J Nucl Cardiol 12: 294-301.
3. Tawakol A, Migrino RQ, Bashian GG, Bedri S, Vermylen D, et al. (2006) In vivo 18F-fluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patients. J Am Coll Cardiol 48: 1818-1824 doi:10.1016/j.jacc.2006.05.076.
4. Rudd JHF, Myers KS, Bansilal S, Machac J, Rafique A, et al. (2007) (18)Fluorodeoxyglucose positron emission tomography imaging of atherosclerotic plaque inflammation is highly reproducible: implications for atherosclerosis therapy trials. J Am Coll Cardiol 50: 892-896 doi:10.1016/j.jacc.2007.05.024.
5. Rudd JHF, Hyafil F, Fayad ZA, (2009) Inflammation imaging in atherosclerosis. Arterioscler Thromb Vasc Biol 29: 1009-1016 doi:10.1161/ATVBAHA.108.165563.
6. Hiari N, Rudd JHF, (2011) FDG PET imaging and cardiovascular inflammation. Curr Cardiol Rep 13: 43-48 doi:10.1007/s11886-010-0150-5.
7. Ogawa M, Ishino S, Mukai T, Asano D, Teramoto N, et al. (2004) (18)F-FDG accumulation in atherosclerotic plaques: immunohistochemical and PET imaging study. J Nucl Med 45: 1245-1250.
8. Hyafil F, Cornily J-C, Rudd JHF, Machac J, Feldman LJ, et al. (2009) Quantification of inflammation within rabbit atherosclerotic plaques using the macrophage-specific CT contrast agent N1177: a comparison with 18F-FDG PET/CT and histology. J Nucl Med 50: 959-965 doi:10.2967/jnumed.108.060749.
9. Silvola JMU, Saraste A, Laitinen I, Savisto N, Laine VJO, et al. (2011) Effects of age, diet, and type 2 diabetes on the development and FDG uptake of atherosclerotic plaques. JACC Cardiovasc Imaging 4: 1294-1301 doi:10.1016/j.jcmg.2011.07.009.
10. Ross R, (1999) Atherosclerosis-an inflammatory disease. N Engl J Med 340: 115-126 doi:10.1056/NEJM199901143400207.
11. Libby P, Ridker PM, Maseri A, (2002) Inflammation and atherosclerosis. Circulation 105: 1135-1143.
12. Fueger BJ, Czernin J, Hildebrandt I, Tran C, Halpern BS, et al. (2006) Impact of animal handling on the results of 18F-FDG PET studies in mice. J Nucl Med 47: 999-1006.
13. Qi J, Leahy RM, Cherry SR, Chatziioannou A, Farquhar TH, (1998) High-resolution 3D Bayesian image reconstruction using the microPET small-animal scanner. Phys Med Biol 43: 1001-1013.
14. Fleige S, Pfaffl MW, (2006) RNA integrity and the effect on the real-time qRT-PCR performance. Mol Aspects Med 27: 126-139 doi:10.1016/j.mam.2005.12.003.
15. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, et al. (2002) Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 3: RESEARCH0034.
16. Hellemans J, Mortier G, De Paepe A, Speleman F, Vandesompele J, (2007) qBase relative quantification framework and software for management and automated analysis of real-time quantitative PCR data. Genome Biol 8: R19 doi:10.1186/gb-2007-8-2-r19.
17. Pauwels EK, Ribeiro MJ, Stoot JH, McCready VR, Bourguignon M, et al. (1998) FDG accumulation and tumor biology. Nucl. Med. Biol. 25: 317-322.
18. Sheikine Y, Akram K, (2010) FDG-PET imaging of atherosclerosis: Do we know what we see? Atherosclerosis 211: 371-380 doi:10.1016/j.atherosclerosis.2010.01.002.
19. Yadav A, Saini V, Arora S, (2010) MCP-1: chemoattractant with a role beyond immunity: a review. Clin Chim Acta 411: 1570-1579 doi:10.1016/j.cca.2010.07.006.
20. Zernecke A, Shagdarsuren E, Weber C, (2008) Chemokines in atherosclerosis: an update. Arterioscler Thromb Vasc Biol 28: 1897-1908 doi:10.1161/ATVBAHA.107.161174.
21. Boisvert WA, Rose DM, Johnson KA, Fuentes ME, Lira SA, et al. (2006) Up-regulated expression of the CXCR2 ligand KC/GRO-alpha in atherosclerotic lesions plays a central role in macrophage accumulation and lesion progression. Am J Pathol 168: 1385-1395.
22. Gu L, Okada Y, Clinton SK, Gerard C, Sukhova GK, et al. (1998) Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell 2: 275-281.
23. Zhang S, Wang X, Zhang L, Yang X, Pan J, et al. (2011) Characterization of monocyte chemoattractant proteins and CC chemokine receptor 2 expression during atherogenesis in apolipoprotein E-null mice. J Atheroscler Thromb 18: 846-856.
24. Cook-Mills JM, Marchese ME, Abdala-Valencia H, (2011) Vascular cell adhesion molecule-1 expression and signaling during disease: regulation by reactive oxygen species and antioxidants. Antioxid Redox Signal 15: 1607-1638 doi:10.1089/ars.2010.3522.
25. O'Brien KD, Allen MD, McDonald TO, Chait A, Harlan JM, et al. (1993) Vascular cell adhesion molecule-1 is expressed in human coronary atherosclerotic plaques. Implications for the mode of progression of advanced coronary atherosclerosis. J Clin Invest 92: 945-951 doi:10.1172/JCI116670.
26. Nakashima Y, Raines EW, Plump AS, Breslow JL, Ross R, (1998) Upregulation of VCAM-1 and ICAM-1 at atherosclerosis-prone sites on the endothelium in the ApoE-deficient mouse. Arterioscler Thromb Vasc Biol 18: 842-851.
27. Stephen SL, Freestone K, Dunn S, Twigg MW, Homer-Vanniasinkam S, et al. (2010) Scavenger receptors and their potential as therapeutic targets in the treatment of cardiovascular disease. Int J Hypertens 2010: 646929 doi:10.4061/2010/646929.
28. Ramprasad MP, Terpstra V, Kondratenko N, Quehenberger O, Steinberg D, (1996) Cell surface expression of mouse macrosialin and human CD68 and their role as macrophage receptors for oxidized low density lipoprotein. Proc Natl Acad Sci USA 93: 14833-14838.
29. Pedersen SF, Graebe M, Fisker Hag AM, Højgaard L, Sillesen H, et al. (2010) Gene expression and 18FDG uptake in atherosclerotic carotid plaques. Nucl Med Commun 31: 423-429 doi:10.1097/MNM.0b013e32833767e0.
30. Cho H-J, Cho H-J, Kim H-S, (2009) Osteopontin: a multifunctional protein at the crossroads of inflammation, atherosclerosis, and vascular calcification. Curr Atheroscler Rep 11: 206-213.
31. Matsui Y, Rittling SR, Okamoto H, Inobe M, Jia N, et al. (2003) Osteopontin deficiency attenuates atherosclerosis in female apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 23: 1029-1034 doi:10.1161/01.ATV.0000074878.29805.D0.
32. Ström A, Franzén A, Wängnerud C, Knutsson A-K, Heinegård D, et al. (2004) Altered vascular remodeling in osteopontin-deficient atherosclerotic mice. J. Vasc. Res. 41: 314-322 doi:10.1159/000079205.
33. Kataoka H, Kume N, Miyamoto S, Minami M, Moriwaki H, et al. (1999) Expression of lectinlike oxidized low-density lipoprotein receptor-1 in human atherosclerotic lesions. Circulation 99: 3110-3117.
34. Mehta JL, Sanada N, Hu CP, Chen J, Dandapat A, et al. (2007) Deletion of LOX-1 reduces atherogenesis in LDLR knockout mice fed high cholesterol diet. Circ Res 100: 1634-1642 doi:10.1161/CIRCRESAHA.107.149724.
35. Hu C, Dandapat A, Sun L, Chen J, Marwali MR, et al. (2008) LOX-1 deletion decreases collagen accumulation in atherosclerotic plaque in low-density lipoprotein receptor knockout mice fed a high-cholesterol diet. Cardiovasc Res 79: 287-293 doi:10.1093/cvr/cvn110.
36. Sluimer JC, Gasc J-M, van Wanroij JL, Kisters N, Groeneweg M, et al. (2008) Hypoxia, hypoxia-inducible transcription factor, and macrophages in human atherosclerotic plaques are correlated with intraplaque angiogenesis. J Am Coll Cardiol 51: 1258-1265 doi:10.1016/j.jacc.2007.12.025.
37. Gao L, Chen Q, Zhou X, Fan L (2012) The role of hypoxia-inducible factor 1 in atherosclerosis. J Clin Pathol. doi:10.1136/jclinpath-2012-200828.
38. Loboda A, Jozkowicz A, Dulak J, (2010) HIF-1 and HIF-2 transcription factors-similar but not identical. Mol. Cells 29: 435-442 doi:10.1007/s10059-010-0067-2.
39. Vuorio T, Jauhiainen S, Ylä-Herttuala S, (2012) Pro- and anti-angiogenic therapy and atherosclerosis with special emphasis on vascular endothelial growth factors. Expert Opin Biol Ther 12: 79-92 doi:10.1517/14712598.2012.641011.
40. Libby P, Folco E, (2011) Tension in the plaque: hypoxia modulates metabolism in atheroma. Circ Res 109: 1100-1102 doi:10.1161/RES.0b013e31823bdb84.
41. Camera M, Brambilla M, Facchinetti L, Canzano P, Spirito R, et al. (2012) Tissue factor and atherosclerosis: not only vessel wall-derived TF, but also platelet-associated TF. Thromb. Res. 129: 279-284 doi:10.1016/j.thromres.2011.11.028.
42. Hatakeyama K, Asada Y, Marutsuka K, Sato Y, Kamikubo Y, et al. (1997) Localization and activity of tissue factor in human aortic atherosclerotic lesions. Atherosclerosis 133: 213-219.
43. Tilley RE, Pedersen B, Pawlinski R, Sato Y, Erlich JH, et al. (2006) Atherosclerosis in mice is not affected by a reduction in tissue factor expression. Arterioscler Thromb Vasc Biol 26: 555-562 doi:10.1161/01.ATV.0000202028.62414.3c.
44. Westrick RJ, Bodary PF, Xu Z, Shen YC, Broze GJ, et al. (2001) Deficiency of tissue factor pathway inhibitor promotes atherosclerosis and thrombosis in mice. Circulation 103: 3044-3046.
45. Owens AP, Passam FH, Antoniak S, Marshall SM, McDaniel AL, et al. (2012) Monocyte tissue factor-dependent activation of coagulation in hypercholesterolemic mice and monkeys is inhibited by simvastatin. J. Clin. Invest. 122: 558-568 doi:10.1172/JCI58969.
46. Maier T, Güell M, Serrano L, (2009) Correlation of mRNA and protein in complex biological samples. FEBS Lett 583: 3966-3973 doi:10.1016/j.febslet.2009.10.036.